EcoDrugPlus

Purinergic Receptor P2y12

Ensembl ID : ENSOMYG00000018214
Gene Symbol: P2RY12
1 Cross references
174 Possible Orthologues:

Purinergic Receptor P2y12

Ensembl ID : ENSOMYG00000043107
Gene Symbol: P2RY12
1 Cross references
174 Possible Orthologues:

Putative Sodium Hydrogen Exchanger 3b

Ensembl ID : ENSOMYG00000003588
Gene Symbol: NHE3B
3 Cross references
222 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSOMYG00000019415
Gene Symbol: P2RY4
1 Cross references
159 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSOMYG00000043984
Gene Symbol: P2RY4
1 Cross references
160 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSOMYG00000040638
Gene Symbol: P2RY6
1 Cross references
176 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSOMYG00000041638
Gene Symbol: P2RY6
1 Cross references
176 Possible Orthologues:

Receptor (Tnfrsf)-Interacting Serine-Threonine Kinase 1, Like

Ensembl ID : ENSOMYG00000026838
Gene Symbol: RIPK1L
1 Cross references
192 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSOMYG00000022499
Gene Symbol: RAMP1
1 Cross references
183 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSOMYG00000015533
Gene Symbol: RAMP1
1 Cross references
186 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSOMYG00000009723
Gene Symbol: RPTOR
1 Cross references
205 Possible Orthologues:

Ret Proto-Oncogene Receptor Tyrosine Kinase

Ensembl ID : ENSOMYG00000028196
Gene Symbol: RET
2 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).